Using the International Pandemic Instrument to Revitalize the Innovation Ecosystem for Antimicrobial R&D.
J Law Med Ethics
; 50(S2): 47-54, 2022.
Article
in English
| MEDLINE | ID: covidwho-2253459
ABSTRACT
The inclusion of antimicrobial resistance (AMR) and increased research and development (R&D) capabilities in the most recent outline of the World Health Organization's (WHO's) international pandemic instrument signals an opportunity to reshape pharmaceutical R&D system in favour of antimicrobial product development. This article explains why the current innovation ecosystem has disadvantaged the creation of antimicrobial products for human use. It also highlights how the COVID-19 pandemic experience can inform and stimulate international cooperation to implement innovative R&D incentives to bring new, life-saving antimicrobial products to the market.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Anti-Infective Agents
Limits:
Humans
Language:
English
Journal:
J Law Med Ethics
Journal subject:
Nursing
/
Ethics
/
Jurisprudence
/
Medicine
/
Health Services Research
Year:
2022
Document Type:
Article
Affiliation country:
Jme.2022.79
Similar
MEDLINE
...
LILACS
LIS